FDA
-
-
-
-
-
-
-
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
-
-
-
-
-
-
-
Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)
-
-
-
-
-
-
-
Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System
-
-
-
-
-
-
-
Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Prev
-
-
-
-
-
-
-
Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare® System vs Restasis®
-
-
-
-
-
-
-
Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data
-
-
-
-
-
-
-
Sight Sciences (SGHT) Receives FDA 510(k) Clearance of the TearCare System for Treatment of Meibomian Gland Dysfunction, the Leading Cause of Dry Eye Disease
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

